People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

Researchers delivered a dose of the “love hormone” oxytocin via a nasal spray to participants and found that it decreased ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

There was no effect of insulin in the larger cohort using the second device. In a subsequent Phase 2 study to determine how much insulin entered the brain after nasal delivery, 19 people received 40 ...

A runny nose just might be a runny nose, but a CSF leak could still be a possible cause of your nasal discharge. Amanda MacMillan is a health and science writer and editor. Her work appears across ...